Another orally administered small molecule inhibitor of BTK, which has also been reported to have off-target activity against the ERBB/EGFP family, ibrutinib, is an FDA-approved drug for hematological diseases [65,66,67]. The gene discussed is BTK; the disease is hematologic disorder.